F. Caprioni

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.

P. Malfertheiner, H. Friess, E. Van Cutsem, 2008, The journal of supportive oncology.

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.

A. Santoro, L. Rimassa, M. Tronconi, 2010, European journal of cancer.

First-line single-agent cetuximab in patients with advanced colorectal cancer.

S. Siena, S. Sciallero, S. Mammoliti, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab in the treatment of metastatic colorectal cancer.

F. Caprioni, G. Fornarini, G. Fornarini, 2007, Future oncology.

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies

C. Bordignon, S. Sciallero, S. Mammoliti, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study

M. Reni, G. Tortora, E. Maiello, 2018, Expert review of pharmacoeconomics & outcomes research.

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.

S. Barni, R. Labianca, C. Boni, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

S. Barni, R. Labianca, V. Torri, 2015, Oncotarget.

Reliability of patient-reported toxicities during adjuvant chemotherapy.

M. Sormani, S. Mammoliti, F. Caprioni, 2023, European journal of cancer.